Tools & Calculators
Edelweiss MSCI India D&W HC 45 RegIDCW-P
as of 25 Mar 2026, 14:03 PM
Invested Amount
Est. Return
Total Value
rated by Value Research
Your principal will be at Very High Risk
Absolute Returns
CAGR
Company Name | Sector | Instrument | Assets |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Healthcare | E | 11.25% |
| Eli Lilly and Co | Healthcare | E | 6.01% |
| Max Healthcare Institute Ltd Ordinary Shares | Healthcare | E | 5.73% |
| Apollo Hospitals Enterprise Ltd | Healthcare | E | 5.69% |
| Divi's Laboratories Ltd | Healthcare | E | 5.17% |
| Cipla Ltd | Healthcare | E | 5.14% |
| Dr Reddy's Laboratories Ltd | Healthcare | E | 4.71% |
| Johnson & Johnson | Healthcare | E | 4.25% |
| Lupin Ltd | Healthcare | E | 3.90% |
| Torrent Pharmaceuticals Ltd | Healthcare | E | 3.46% |
| Fortis Healthcare Ltd | Healthcare | E | 3.12% |
| AbbVie Inc | Healthcare | E | 2.91% |
| Laurus Labs Ltd | Healthcare | E | 2.55% |
| Novartis AG ADR | Healthcare | E | 2.28% |
| Glenmark Pharmaceuticals Ltd | Healthcare | E | 2.24% |
| Merck & Co Inc | Healthcare | E | 2.20% |
| Aurobindo Pharma Ltd | Healthcare | E | 2.15% |
| Mankind Pharma Ltd | Healthcare | E | 1.88% |
| Alkem Laboratories Ltd | Healthcare | E | 1.82% |
| Amgen Inc | Healthcare | E | 1.48% |
| Ipca Laboratories Ltd | Healthcare | E | 1.44% |
| Abbott Laboratories | Healthcare | E | 1.42% |
| Biocon Ltd | Healthcare | E | 1.41% |
| Thermo Fisher Scientific Inc | Healthcare | E | 1.37% |
| Gilead Sciences Inc | Healthcare | E | 1.31% |
| Intuitive Surgical Inc | Healthcare | E | 1.27% |
| Zydus Lifesciences Ltd | Healthcare | E | 1.25% |
| Aster DM Healthcare Ltd Ordinary Shares | Healthcare | E | 1.03% |
| Danaher Corp | Healthcare | E | 0.95% |
| Stryker Corp | Healthcare | E | 0.94% |
| Gland Pharma Ltd | Healthcare | E | 0.91% |
| Vertex Pharmaceuticals Inc | Healthcare | E | 0.90% |
| Medtronic PLC | Healthcare | E | 0.89% |
| Narayana Hrudayalaya Ltd | Healthcare | E | 0.88% |
| Ajanta Pharma Ltd | Healthcare | E | 0.88% |
| Novo Nordisk AS ADR | Healthcare | E | 0.86% |
| GlaxoSmithKline Pharmaceuticals Ltd | Healthcare | E | 0.73% |
| Piramal Pharma Ltd | Healthcare | E | 0.63% |
| Global Health Ltd | Healthcare | E | 0.62% |
| Regeneron Pharmaceuticals Inc | Healthcare | E | 0.58% |
| Syngene International Ltd | Healthcare | E | 0.52% |
| Becton Dickinson & Co | Healthcare | E | 0.36% |
| Agilent Technologies Inc | Healthcare | E | 0.24% |
| IQVIA Holdings Inc | Healthcare | E | 0.21% |
| Illumina Inc | Healthcare | E | 0.14% |
| Net Receivables/(Payables) | - | CA | 0.17% |
| Clearing Corporation Of India Ltd. | - | CR | 0.15% |
| Accrued Interest | - | CA | 0.00004% |
Equity / Debt / Cash Split
Equity
99.68%
Cash
0.32%
Equity sector allocation
Healthcare
99.68%
Others
0.32%
Asset Management Company

Mirae Asset NYSE FANG+ ETF FoF Reg Gr
Equity
Min. Investment
₹5000
Category Returns
30.89%
48.34%
3Y Returns
+48.34%

DSP Wld Gld Mng Ovrs Eq Omni FoF Gr
Equity
Min. Investment
₹100
Category Returns
30.89%
48.34%
3Y Returns
+45.98%

DSP Wld Gld Mng Ovrs Eq Omni FoF IDCW-R
Equity
Min. Investment
₹100
Category Returns
30.89%
48.34%
3Y Returns
+45.89%
Investment Objective of the Scheme
Key Features of The Fund
5-year return
+13.64%
Fund Manager
Bhavesh Jain
Risk Profile
Very High Risk
Expense Ratio
1.06%
Fund Size
₹174.93 Cr
By signing up I certify terms, conditions & privacy policy